TrialNCT03427060Phase 2Completed
Coversin in PNH in Patients With Resistance to Eculizumab Due to Complement C5 Polymorphisms
Study sponsor: AKARI Therapeutics
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Primary completion2018-11-15Actual
Enrollment · participants1Actual
Source updated2025-05-04Last update listed in the registry record
Version history
Changes to this trial
Pro unlocks the full available history and CSV export. View Pro features
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.